What Safety Data Should You Request from a Supplier of Pharmaceutical Intermediates
2026-06-15
When sourcing pharmaceutical intermediates, safety documentation is non-negotiable. Humanwell recommends that every buyer request a structured set of safety data before approving any supplier. This blog outlines the essential safety documents, presents a verification checklist, and answers the most common questions in the Intermediates Category.
Essential Safety Data to Request
A reliable supplier must provide the following safety documents for each batch of pharmaceutical intermediates:
| Safety Document | Purpose | Update Frequency |
|---|---|---|
| Safety Data Sheet (SDS) | Hazards identification, handling, storage, first aid | Every revision or minimum every 3 years |
| COA (Certificate of Analysis) | Purity, impurity profile, residual solvents | Per batch |
| TDS (Technical Data Sheet) | Physical and chemical properties | Per product |
| Stability Study Report | Degradation trends and storage conditions | Ongoing (accelerated/long-term) |
| Residual Solvent Test Report | Class 1, 2, 3 solvent limits per ICH Q3C | Per batch |
| Genotoxicity Impurity Report | Potential mutagenic impurities per ICH M7 | Per development phase |
Key Data Points to Verify
Before approving a shipment of pharmaceutical intermediates, cross-check these critical safety parameters:
-
Flash point – Determines fire risk during transport and storage.
-
Reactivity profile – Incompatibilities with water, air, acids, bases.
-
Particle size distribution – Impacts dust explosion hazard and operator exposure.
-
Heavy metals content – Must meet ICH Q3D limits.
-
Packing group classification – UN transport code for dangerous goods.
Intermediates Category FAQ
Q1: Are Safety Data Sheets (SDS) legally required for pharmaceutical intermediates under REACH or OSHA?
A1: Yes. Under REACH (EC 1907/2006) and OSHA Hazard Communication Standard (29 CFR 1910.1200) , any supplier of pharmaceutical intermediates must provide an SDS if the substance is classified as hazardous. Even for non-hazardous intermediates, an SDS is strongly recommended because downstream processing conditions (e.g., heating, milling) may create unforeseen hazards. Failure to provide a compliant SDS can result in supply chain rejection and regulatory fines.
Q2: How can I verify that a supplier's stability data for intermediates is reliable?
A2: Request the full stability protocol including batch number, packaging, storage conditions (temperature/humidity), and testing intervals (0, 3, 6, 12 months). Reliable data follows ICH Q1A(R2) guidelines: 25°C/60% RH for long-term and 40°C/75% RH for accelerated studies. Cross-check that degradation products are identified and quantified. For pharmaceutical intermediates, any impurity increase above 0.5% during the proposed shelf life must be justified. Humanwell provides full stability reports from GMP-certified labs.
Q3: What genotoxicity data should I request for early-phase intermediates?
A3: Request an ICH M7 assessment that identifies potential mutagenic impurities with a threshold of toxicological concern (TTC) of 1.5 µg/day. The supplier must provide either:
-
Analytical method validation for each impurity (LC-MS/MS or GC-MS), or
-
A purge factor calculation demonstrating removal during downstream synthesis.
For intermediates used in Phase I/II clinical trials, a bacterial reverse mutation (Ames) test on the intermediate itself is recommended. Humanwell supplies pharmaceutical intermediates with full ICH M7-compliant dossiers.
Best Practices for Safety Data Management
To maintain compliance across the Intermediates Category:
-
Standardize request forms – Use a single template for all suppliers.
-
Set expiry alerts – SDS and stability reports must be renewed.
-
Audit annually – Review safety data during supplier quality audits.
Contact Us
Humanwell ensures every shipment of pharmaceutical intermediates is accompanied by complete, auditable safety data packs including SDS, COA, stability, and genotoxicity reports. Contact our regulatory support team today to request a sample data package or schedule a supplier qualification review.